{'fraction_non_alphanumeric': 0.01853997682502897, 'fraction_numerical': 0.0, 'mean_word_length': 4.874149659863946, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the SAVE‐ONCO trial control arm

these seem to deliver a significant survival benefit, though comparative studies and trials have not been done. In univariate and multivariate analyses, SCT was associated with a better OS, consistent with previous reports. Our study is the largest one to compare SCT to non-SCT patients in a real-world setting and adds to the growing literature in support of SCT in this population. One might argue that patients who received SCT as initial therapy are likely healthier and their improved OS may be in part due to this, though our population was relatively young and had a low Charlson– Deyo comorbidity score. Our study has several limitations. First, given our small sample size, our statistical analysis was limited. Also, given the difficulty in diagnosis of HSTCL, our cohort may not be representative of the entire HSTCL population. However, ours is the largest study to date to describe the predictors of mortality in HSTCL, and this study can be expanded as more cases accumulate over time. In addition, given the limitations of the NCDB itself, we were unable to provide details of the initial chemotherapy given or relapse. In conclusion, the incidence of HSTCL has at least doubled in the past decade with the highest predilection among Blacks. The OS remains poor and disturbingly has not improved over time. The use of SCT may be associated with a better outcome, supporting the earlier findings from smaller retrospective studies. We expect a further increase in the incidence of HSCTL as more patients in the US receive organ transplants and become immunosuppressed.